The Faculty of Medicine at Bangkok’s Chulalongkorn University has put out a call for healthy volunteers to take part in trials of its Covid-19 mRNA vaccine.
TriLink enables Chula VRC to take its Covid-19 vaccine into a First in Human (FIH) phase 1 clinical trial in Thailand with mRNA
With Covid-19 battering Thailand and the third wave bringing the Sinovac-resistant Delta variant to the forefront of the pandemic,
This episode talks about the procedures of vaccine invention and manufacturing and about the new technology of mRNA
Prof Kiat Ruxrungtham from the Center of Excellence in Vaccine Research Center and Development. Photo courtesy of Chulalongkorn Hospital
Kiat Ruxrungtham isn’t content to see Thailand wait in line to buy vaccines from another country.
The first phase of clinical trial on volunteers who have passed the screening process and deemed to be in good health
Thailand is tightening border controls as the country faces its worst coronavirus outbreak.
Chulalongkorn University’s mRNA Covid-19 vaccine, ChulaCov19, began its first round of human trials
ChulaCov19 designer Kiat Ruxrungtham talks about his aim to make Thailand an mRNA vaccine hub
A race to develop a vaccine against Covid-19 is paving the way for researchers in Thailand to produce inoculations against other diseases.
Organized by: Chula Vaccine Research Center (Chula VRC), Faculty of Medicine and Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Venue: 12th Floor, Bhumisiri Building, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Free registration: 150 participants on the first come first serve basis
Deadline: November 30, 2018
Topics
- Effect of SQ-21 and aluminum hydroxide gel on physical and adjuvant properties of Army Liposome Formulations (ALF)
- Development of a cationic liposome-based adjuvant containing a TLR4 agonist
- Immunogenicity and protective efficacy vaccine studies using Army Liposome Formulations (ALF) in NHP models
- Assessment of the efficacy of nanoparticle-entrapped porcine reproductive and respiratory syndrome virus (PRRSV) vaccine
- Polyvalent display on nanoparticles as the efficient delivery platform for eliciting immune responses of macromolecules
To attend the Global Vaccine and Immunization Research Forum (GVIRF) 2018.
Organized: Chula Vaccine and Research Center (Chula VRC)
Sponsor: Thailand Centre of Excellent for Life Sciences (TCELS), National Vaccine Institute (Public Organization), National Science and Technology Development Agency (NSTDA), Chulalongkorn University
Venue: 12th Floor, Bhumisiri Building, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Free registration: 150 participants on the first come first serve basis
Deadline: 31 October 2017
Topics
30 November 2017
- Nucleic Acid-based Vaccine; Synthetic vector-mediated IgG generated in vivo confers protective immunity against Emerging Viral Infection
- Zika mRNA Vaccine
- Dengue DNA Vaccine
- HIV
- mRNA-based vaccine
- DNA Vaccine: from design to production
1 December 2017
- Allergy Vaccine Overview
- HDM Allergy DNA-based Vaccine
- Pre-clinical development
- In vivo expression of plasmid encoded IgG for immune check point targets by synthetic DNA: a new tool for cancer immunotherapy
Sponsor: National Science and Technology Development Agency (NSTDA) and Thailand Centre of Excellent for Life Science (TCELS)
Venue: 12th Floor, Bhumisirimangkhlanusorn, Faculty of Medicine and Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Free registration with limited number of participants: 100 for lecture, 20 for hand-on workshop
Deadline: 31 August 2016.
Registration by e-mail: Sunee Sirivichayakul (Sunee.s@chula.ac.th)
Topics
21 Sept 2016
- Adjuvant Updates: past, present and how to choose the best adjuvant
- TLR agonists as potential vaccine adjuvants
- Liposome and related issues
- Mucosal adjuvats
- Emulsion-type (lipid based) adjuvants (MF59, AS03, Freund’s, microemulsion, nanoemulsion) and biopolymeric adjuvants
- Adjuvants for Transcutaneous immunization
- Mixed adjuvant formulations
- Adjuvants for DNA vaccines
22 Sept 2016
- Virus-like particle (VLP) Updates
- Specific VLP for dengue
- Bacteriophage-based VLP platform
- VLP production from animal cells
- Liposome-related workshop: brief overview
- Liposome-related hand-on workshop
23 Sept 2016
- VLP-related hand-on workshop
- Meet the experts
